Zaash Labs publishes analyst-led market intelligence reports on newly approved drugs and medical devices. Each report delivers a revenue forecast, a competitive assessment, a geographic adoption outlook and a regulatory risk review, with every figure sourced and every assumption disclosed.
Investment committees, business development teams and market access leads act in the days that follow an approval. Conventional syndicated research is comprehensive, but it is often priced and paced for a different purpose.
| Conventional syndicated report | Zaash Labs report | |
|---|---|---|
| Price | USD 3,000 to 5,000 or more | USD 650, with internal team sharing included |
| Length | 150 to 200 pages | 25 pages in a consistent structure |
| Timing | Weeks or months after the event | Within five business days of approval |
| Forecast transparency | Outputs often presented without the underlying model | Full assumptions, patient funnel and sensitivity analysis printed |
Every report follows the same eight sections, so readers know exactly where to find each answer.
The investment and commercial verdict in a single page.
Mechanism of action, indication, pivotal trial design, efficacy and safety against the standard of care.
Eligible population, pricing and uptake modelled to peak sales, with base, upside and downside cases.
Comparison against approved therapies and the Phase II and III pipeline, with a market share outlook.
United States, EU5, Japan and China: launch sequencing, pricing and reimbursement outlook.
Label restrictions, health technology assessment hurdles and safety considerations.
Dedicated guidance for investors, business development and market access teams.
Sources, methodology and model assumptions, so every figure can be verified.
Each report is led and verified by an analyst with clinical training in pharmacy and experience across pharmaceuticals, medical devices and clinical AI. The process is the same for every report.
FDA and EMA labels, pivotal trial records on ClinicalTrials.gov, company filings and disclosures, peer-reviewed epidemiology and published HTA decisions. For devices: FDA summaries of safety and effectiveness and De Novo decision summaries, MAUDE reports, CMS coverage and coding decisions, and human factors evidence.
A bottom-up patient funnel, net price assumptions and an uptake curve benchmarked against comparable launches.
Trial results are interpreted in their clinical context, including endpoints missed, safety signals and real prescribing behaviour.
Every figure is traced back to its source, and all assumptions are printed in the appendix for the reader to test.
AI assists with our research and drafting. What it cannot provide on its own is verified sources, sound clinical judgement and accountability. Fully automated market reports are now widespread and inexpensive, but they are difficult to rely on for decisions with real money attached. The difference shows in the detail.
| Typical fully automated report | Zaash Labs report | |
|---|---|---|
| Sources | Unclear or unverifiable, and sometimes invented citations | Every source named and cited in the appendix |
| Numbers | Figures that read plausibly but cannot be traced or reproduced | A transparent model you can audit line by line |
| Clinical judgement | Restates press releases and company positioning | Interprets missed endpoints, safety signals and real-world use |
| Currency | Limited by training data, often months out of date | Researched from documents published in the days after approval |
| Accountability | No named author and no one to question | An accountable research team that answers your questions about the work |
Review the free executive summary first, then purchase the full report.
Executive verdict, pivotal trial comparison, revenue forecast to 2031, competitive landscape, geographic adoption, six regulatory and access risks, and implications by role.
Instant PDF download · Internal team sharing included
Secure card checkout by Stripe. Download your report straight after payment.
Need an invoice for your finance team? Request one.
New: medical device summaries Optune Pax in pancreatic cancer, Selution SLR in in-stent restenosis and Aletta robotic blood draw · See device reports · See pharma reports
Start with the free two-page executive summary, or order the full 25-page report. One short form, either way.
Two pages: the verdict, the headline forecast with base, upside and downside cases, and the key evidence. Instant PDF.
Get the free summary →25 pages with the full model, competitive landscape, geographic adoption, regulatory and access risk, and every source. Internal team sharing included. Pay by card or invoice.
Order a full report →Our target is publication within five business days of a major approval or Phase III readout.
FDA and EMA labels, ClinicalTrials.gov, company filings and disclosures, peer-reviewed epidemiology and published HTA decisions. All sources are listed in each report's appendix. We do not rely on undisclosed datasets.
Yes, as an assistant. AI helps with research and drafting. Every figure, assumption and conclusion is then checked against cited sources by experienced industry analysts, who sign off on the final report. You can question any number and we will show you where it came from.
Yes. A single purchase covers internal sharing across your team.
For reports marked available now, pay by card through our secure Stripe checkout and download the report straight away. Reports marked on order are written after you order and delivered by email within five business days. If your organisation needs to pay by invoice, choose invoice in the order form and we will send it to your finance team.
Yes. Custom reports are available on request. Choose "Request coverage" in the order form and tell us which product and indication you need.
No. Our reports are market research to support business decisions.
Zaash Labs is a Toronto-based healthcare market intelligence firm built by industry practitioners, with backgrounds spanning pharmacy, regulatory strategy, human factors engineering and commercial analytics across pharmaceutical, biotech and medical device work. We focus on one moment: when a Phase III success or a device approval turns a product into a market.
Each report is led by our core analyst team and strengthened by a growing network of independent industry experts: specialists in commercial strategy, market access, clinical development and medical devices who review assumptions and contribute therapy area knowledge, so every forecast reflects how the market actually works.
We do not accept sponsored coverage, and we do not sell or share the details you give us.
Need a product we have not covered, a custom report or an invoice? We reply within one business day.
hello@zaashlabs.co
Toronto, Ontario, Canada
Are you an industry professional in pharma, biotech, medtech or market access? We work with independent experts on paid, flexible report projects.
Apply to join →